Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass thereby improving body composition and physical function. Sabizabulin, a microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease.
Company Details
- Employees
- 53
- Founded
- -
- Address
- 2916 North Miami Ave, Miami,fl 33137-3212,united States
- Phone
- 305-509-6897
- in****@****are.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.verupharma.com
- HQ
- Miami, FL
Veru Inc. Questions
Veru Inc.'s helpline number is 305-509-6897
Veru Inc.'s website is http://www.verupharma.com
Veru Inc.'s LinkedIn profile is https://www.linkedin.com/company/veru-pharma
Veru Inc. has
53 employees.
View email and phone details for 53
employees at Veru Inc..
Veru Inc.'s industry is
Biotechnology Research
Veru Inc.'s top competitors are
Akero Therapeutics,
Female Health Company,
Allakos Inc,
Manas Ai,
Atalanta Therapeutics,
Vertex Pharmaceuticals,
Sage Therapeutics,
Helicore Biopharma,
Viridian Therapeutics, Inc.,
Maze Therapeutics.
Veru Inc.'s support email address is info@veruhealthcare.com
Veru Inc.'s categories are Biotechnology Research
Veru Inc.'s founding year is 2014
